GLP-2: The Gut Repair Peptide
Gut Peptide Hormones
54%
In clinical trials, 54% of short bowel syndrome patients on teduglutide, a GLP-2 analog, achieved at least one additional parenteral nutrition-free day per week.
Jeppesen, Therapeutic Advances in Gastroenterology, 2012
Jeppesen, Therapeutic Advances in Gastroenterology, 2012
View as imageYour gut lining replaces itself every three to five days, making it one of the most rapidly renewing tissues in the human body. The peptide hormone that orchestrates much of this renewal is glucagon-like peptide-2 (GLP-2), a 33-amino-acid signal released by the same intestinal L-cells that produce its better-known sibling, GLP-1. While GLP-1 has captured public attention for its role in diabetes and weight loss, GLP-2 operates on the gut peptide network with a different mandate: growing, repairing, and maintaining the intestinal epithelium. Its therapeutic analog, teduglutide, became the first approved drug specifically designed to harness this intestinotrophic activity, reducing parenteral nutrition dependence in patients with short bowel syndrome.[1]
Key Takeaways
- GLP-2 is a 33-amino-acid peptide produced by intestinal L-cells that stimulates crypt cell proliferation and inhibits epithelial apoptosis (Orhan et al., 2018)
- Native GLP-2 has a half-life of approximately 7 minutes; teduglutide, a DPP-IV resistant analog, extends this to 3-5 hours (Yazbeck, 2010)
- In SBS clinical trials, 54% of teduglutide-treated patients achieved at least one additional parenteral nutrition-free day per week (Jeppesen, 2012)
- GLP-2 reduces intestinal permeability through tight junction protein regulation, independent of its growth effects (Hadjiyanni et al., 2009)
- GLP-2 increases mesenteric blood flow acutely, enhancing nutrient absorption capacity (Galsgaard et al., 2025)
- The GLP-2 receptor is expressed on enteric neurons and subepithelial myofibroblasts, not directly on intestinal epithelial cells (Anini et al., 2007)
What GLP-2 Is and Where It Comes From
GLP-2 is a proglucagon-derived peptide, meaning it is cleaved from the same precursor protein that produces GLP-1 and glucagon. In the intestinal L-cells, concentrated in the terminal ileum and proximal colon, prohormone convertase 1/3 processes proglucagon to release both GLP-1 and GLP-2 in equimolar amounts after nutrient ingestion.[2]
This co-secretion is physiologically significant. When you eat, the same L-cell activation that releases GLP-1 to stimulate insulin and suppress appetite simultaneously releases GLP-2 to prepare the intestinal lining for nutrient absorption. The two peptides complement each other: GLP-1 manages systemic glucose handling while GLP-2 ensures the absorptive surface itself is maintained and functional.
Native GLP-2 is rapidly degraded by dipeptidyl peptidase-IV (DPP-IV), the same enzyme that breaks down GLP-1. The result is a circulating half-life of approximately 7 minutes, too brief for therapeutic use without modification.[2] This short half-life also means that GLP-2's physiological effects are tightly coupled to feeding: the signal rises after meals and falls quickly between them.
Beyond the gut, GLP-2 is also produced locally within pancreatic islets. He and colleagues demonstrated that human islet cells produce GLP-2 and that it plays a role in balancing inflammation through crosstalk between islet cells and immune cells.[3] This non-intestinal source of GLP-2 suggests the peptide has broader immunomodulatory functions than initially appreciated.
How GLP-2 Repairs and Grows Intestinal Tissue
GLP-2's primary function is intestinotrophic: it promotes growth and maintenance of the intestinal mucosa. It does this through two complementary cellular mechanisms, stimulating proliferation of crypt stem cells and inhibiting apoptosis (programmed cell death) of mature enterocytes along the villus.[4]
The signaling pathway is indirect and more complex than initially assumed. The GLP-2 receptor (GLP-2R) is not expressed directly on intestinal epithelial cells. Instead, it sits on enteric neurons and subepithelial myofibroblasts within the lamina propria.[5] When GLP-2 binds these receptors, it triggers a paracrine cascade: the subepithelial cells release growth factors, particularly insulin-like growth factor-1 (IGF-1), ErbB ligands, and keratinocyte growth factor, which then act on the epithelial cells to drive proliferation.
Anini and colleagues showed that phosphatidylinositol-3 kinase-gamma (PI3K-gamma) is a critical intermediary in this pathway. In PI3K-gamma knockout mice, GLP-2's ability to stimulate intestinal growth was abolished, confirming that the G protein-coupled receptor signaling through this kinase is essential for the trophic response.[5]
The net effect of these pathways is measurable expansion of the intestinal mucosa: increased crypt depth, taller villi, and greater mucosal surface area. In animal models, chronic GLP-2 administration produces visible increases in small intestinal weight and length. In a neonatal pig model studying long-acting GLP-2 analogs, treatment produced linear intestinal growth that persisted even after treatment discontinuation, suggesting structural changes rather than transient stimulation.[6]
Beyond Growth: Barrier Function and Blood Flow
GLP-2's effects extend well beyond simple tissue growth. Three additional mechanisms contribute to its role in gut maintenance.
Barrier function. The intestinal epithelium forms a selective barrier that must simultaneously absorb nutrients and exclude pathogens. GLP-2 strengthens this barrier by upregulating tight junction proteins between epithelial cells, including claudins and occludin, which seal the spaces between adjacent cells. Hadjiyanni and colleagues demonstrated that GLP-2 reduced intestinal permeability in nonobese diabetic mice, an effect that was independent of its proliferative actions.[7] The permeability reduction was measurable within days, suggesting a direct regulatory effect on existing tight junctions rather than a secondary consequence of tissue growth. This barrier-enhancing effect has implications for conditions characterized by increased intestinal permeability, including inflammatory bowel disease, celiac disease, and critical illness where gut barrier failure can drive systemic inflammation and sepsis.
Mesenteric blood flow. GLP-2 acutely increases blood flow through the superior mesenteric artery, the primary blood supply to the small intestine. Galsgaard and colleagues confirmed this effect in 2025, showing that GLP-2 and GIP both independently increase mesenteric blood flow, and that this effect operates independently of nitric oxide and vasoactive intestinal peptide (VIP) pathways.[8] Enhanced blood flow delivers more oxygen and nutrients to the intestinal wall, supporting both absorption and tissue repair.
Gastric motility. GLP-2 slows gastric emptying and reduces gastric acid secretion, extending the time that nutrients spend in contact with the absorptive surface. This complements the actions of other gut peptides like CCK and ghrelin that regulate different phases of digestive transit.
Teduglutide: From Peptide to Approved Drug
The therapeutic potential of GLP-2 was limited by its 7-minute half-life. Teduglutide solved this by substituting a single amino acid (alanine to glycine at position 2), which renders the molecule resistant to DPP-IV cleavage. The result is a half-life of 3 to 5 hours, sufficient for once-daily subcutaneous injection.[2]
Teduglutide (marketed as Gattex in the US and Revestive in Europe) was approved in 2012 for adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. SBS occurs when surgical resection, congenital defects, or disease removes enough small intestine that the remaining gut cannot absorb adequate nutrition. Patients often depend on intravenous feeding (parenteral nutrition) for survival, a treatment that carries risks of liver disease, catheter-related bloodstream infections, metabolic bone disease, and severe reductions in quality of life. The cost of home parenteral nutrition in the United States exceeds $100,000 per year per patient, and the social burden of being tethered to infusion pumps for 10 to 16 hours daily is substantial.[1]
Clinical Evidence in Short Bowel Syndrome
The pivotal trial for teduglutide randomized SBS patients dependent on parenteral support to teduglutide 0.05 mg/kg/day or placebo. After 24 weeks, the teduglutide group demonstrated reductions in parenteral nutrition volume that were sustained through 2 years of treatment. Across the clinical program, 54% of all patients achieved at least one additional infusion-free day per week.[1]
Harpain and colleagues documented longer-term outcomes in a 2022 analysis. Among SBS patients treated with teduglutide, parenteral nutrition volume decreased progressively, and a subset of patients achieved complete enteral autonomy, meaning they no longer required any intravenous nutrition. The improvements correlated with increased plasma citrulline levels, a biomarker of functional intestinal epithelial mass, confirming that the clinical benefit reflected genuine mucosal adaptation rather than symptomatic improvement alone.[9]
Pediatric data have extended these findings. In neonatal models, long-acting GLP-2 analogs promoted linear intestinal growth in length, not just mucosal thickening. Hinchliffe and colleagues found that this lengthening effect persisted after treatment discontinuation, suggesting that GLP-2-induced structural growth may be permanent in developing intestines.[6]
Safety: The Neoplasia Question
Because GLP-2 stimulates epithelial proliferation, any growth-promoting therapy raises theoretical concerns about cancer risk. Orhan and colleagues conducted a systematic review of GLP-2's intestinotrophic effects in relation to intestinal neoplasia, examining both preclinical and clinical data.[4]
In animal models, GLP-2 promoted the growth of existing intestinal tumors when administered after tumor initiation, but did not independently initiate neoplasia. The distinction matters: GLP-2 appears to accelerate growth of tissue that is already proliferating, whether normal or neoplastic, rather than causing malignant transformation in healthy tissue.
Clinical monitoring of teduglutide-treated patients has not identified an increased incidence of colorectal cancer, though follow-up periods remain relatively short for cancer epidemiology. Current prescribing guidelines recommend colonoscopy within 6 months before starting teduglutide and repeat surveillance every 5 years during treatment. Patients with active gastrointestinal malignancy are excluded from teduglutide therapy.
The safety profile also includes polyp monitoring. The teduglutide clinical trials reported small intestinal and colonic polyps at rates that require surveillance, though most polyps detected have been benign hyperplastic or inflammatory types rather than adenomas with malignant potential. Gastrointestinal side effects of teduglutide include abdominal pain, nausea, and injection site reactions, which are generally mild and transient. Fluid overload can occur as intestinal absorption improves, requiring careful adjustment of parenteral nutrition volumes during treatment initiation.
The Future: Dual Agonists and New Indications
The separation of GLP-1 and GLP-2 functions into distinct therapeutic programs is beginning to converge. Wismann and colleagues developed novel GLP-1/GLP-2 co-agonist peptides that simultaneously activate both receptors, producing marked effects on gut volume while also improving glycemic control in mice.[10] Such dual agonists could theoretically address both the metabolic and intestinal repair needs of patients with diabetes who also have compromised gut function.
Beyond SBS, GLP-2 and its analogs are being investigated for inflammatory bowel disease (where barrier dysfunction and mucosal damage are central to pathology), radiation enteritis, chemotherapy-induced mucositis, and neonatal necrotizing enterocolitis. The challenge in each case is balancing the beneficial trophic and barrier-enhancing effects against the theoretical proliferative risk in already-inflamed tissue.
Newer GLP-2 analogs with longer half-lives than teduglutide, including glepaglutide and apraglutide, are in clinical development. These aim to improve convenience (less frequent dosing) and potentially achieve greater intestinal adaptation than teduglutide's once-daily regimen. A Phase 3 trial of glepaglutide demonstrated reductions in parenteral support requirements in SBS patients, adding to the expanding clinical evidence base for this peptide class. Additionally, the concept of combining GLP-2 with complementary gut peptides like secretin and gastrin for coordinated digestive optimization remains an active area of preclinical investigation.
The Bottom Line
GLP-2 is a 33-amino-acid intestinal peptide that drives gut epithelial growth, barrier repair, and mesenteric blood flow through indirect paracrine signaling via enteric neurons and subepithelial myofibroblasts. Its therapeutic analog teduglutide has proven effective in reducing parenteral nutrition dependence in short bowel syndrome, with newer analogs and dual GLP-1/GLP-2 agonists expanding the potential applications of this gut repair pathway.